Drug Shortage Report for OBIZUR
Report ID | 121439 |
Drug Identification Number | 02447401 |
Brand name | OBIZUR |
Common or Proper name | Antihemophilic Factor (Recombinant), Porcine Sequence |
Company Name | TAKEDA CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | ANTIHEMOPHILIC FACTOR |
Strength(s) | 500UNIT |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 3 mL single-dose vial |
ATC code | B02BD |
ATC description | VITAMIN K AND OTHER HEMOSTATICS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | 2020-07-30 |
Actual start date | 2020-07-30 |
Estimated end date | 2020-09-15 |
Actual end date | 2020-08-18 |
Shortage status | Resolved |
Updated date | 2020-08-18 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 22 ADELAIDE STREET WEST TORONTO, ONTARIO CANADA M5H 4E3 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-07-30 | English | Compare |
v2 | 2020-07-30 | French | Compare |
v3 | 2020-07-31 | English | Compare |
v4 | 2020-08-18 | English | Compare |
v5 | 2020-08-18 | French | Compare |
Showing 1 to 5 of 5